{
    "code": "02025165",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02025165",
    "time": "2023-02-10 07:10:54",
    "許可證字號": "衛署藥輸字第025165號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "114\/04\/01",
    "發證日期": "99\/04\/01",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA00202516500",
    "中文品名": "癌伏妥錠5毫克",
    "英文品名": "Afinitor 5mg tablets",
    "適應症": "AFINITOR® 合併exemestane 適用於治療荷爾蒙接受體陽性、HER2 受體陰性且之前使用過letrozole 或anastrozole 復發或惡化之停經後晚期乳癌患者。\r\n\r\nAFINITOR® 適用於進展性，無法切除或轉移性分化良好或中度分化(well-differentiated or moderately-differentitated) 之胰臟神經內分泌腫瘤成人患者。\r\n\r\nAFINITOR® 適用於治療在經VEGF-targeted 療法無效後之晚期腎細胞癌患者。\r\n\r\n適用於治療無法切除、局部晚期或轉移之進展性、分化良好、胃腸道(GI)或肺部來源之非功能性神經內分泌腫瘤(NET)成人患者。",
    "劑型": "110錠劑",
    "包裝": "4-1000錠鋁箔盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "EVEROLIMUS",
    "限制項目": "02輸　入 1E須執行Phase IV Study",
    "申請商名稱": "0924601100  台灣諾華股份有限公司",
    "申請商地址": "台北市中山區民生東路三段2號8樓",
    "主製造廠": [
        {
            "製造廠名稱": "FCH0088000  NOVARTIS PHARMA STEIN AG",
            "製造廠廠址": "SCHAFFHAUSERSTRASSE CH-4332 STEIN, SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "1225204000  裕利股份有限公司",
            "製造廠廠址": "桃園市大園區和平里1鄰開和路91號",
            "製造廠公司地址": "",
            "製造廠國別": "TAIWAN",
            "製程": "二級包裝廠"
        },
        {
            "製造廠名稱": "FCH0088200  NOVARTIS PHARMA AG",
            "製造廠廠址": "LICHTSTRASSE 35 CH-4056 BASEL SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "許可證持有者"
        },
        {
            "製造廠名稱": "FSI0001200  LEK PHARMACEUTICALS D.D",
            "製造廠廠址": "KOLODVORSKA CESTA 27, 1234 MENGES, SLOVENIA",
            "製造廠公司地址": "",
            "製造廠國別": "SLOVENIA",
            "製程": "中間體製造"
        }
    ],
    "CCC號列": "30049071005 抗癌藥Anti-cancer preparations",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200099400",
            "成分名稱": "EVEROLIMUS",
            "含量描述": "",
            "含量": "5.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "025165_Afinitor 5mg tablets-108-06-21(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025165&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "依核定草本印妥之仿單_Afinitor 5mg tablets_TWI-250222-111-04-08.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025165&Seq=031&Type=9"
        },
        {
            "title": "025165_Afinitor 5mg_Foil-109-06-03(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025165&Seq=007&Type=8"
        },
        {
            "title": "025165_Afinitor 5mg_FB-109-06-03(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025165&Seq=006&Type=8"
        },
        {
            "title": "癌伏妥錠 5mg_FB-105-02-15.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025165&Seq=005&Type=8"
        }
    ]
}